Other Events ·
EMA grants Orphan Drug Designation to Quoin's QRX003 for Peeling Skin Syndrome
QNRXQuoin Pharmaceuticals Ltd.
The European Medicines Agency has granted Orphan Drug Designation to Quoin Pharmaceuticals' lead product candidate, QRX003, for the treatment of Peeling Skin Syndrome. This designation provides incentive benefits including scientific advice on study protocols, fee reductions, and access to EU grants. If approved for marketing by the EMA, QRX003 will receive 10 years of market exclusivity in Europe for this indication. The company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year-end. Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.